Top Stories
corbevax: Biological E pegs Corbevax price at Rs 990/dose | Hyderabad News
HYDERABAD: Vaccine maker Biological E has decided to price its Covid-19 vaccine Corbevax at Rs 800 per dose, excluding GST, in the private market, which adds up to Rs 990, including taxes and administration charges, even as the pricing for government supply would remain Rs 145 per dose, BE managing director Mahima Datla said on Wednesday.
Datla said this was to ensure government supplies at the most affordable pricing. “It’s a no-profit-no-loss kind of pricing but it won’t help us recover the investments we have made in the deployment of capital infrastructure,” Datla said, pointing out that the company helped save the exchequer about Rs 1,500 crore.
Bio E plans to test vaccine on infants
Datla had earlier indicated to TOIin an exclusive interview that Corbevax would be priced at a premium to Serum Institute’s Covishield as the head-to-head comparator trials it conducted had shown Corbevax’s effectiveness to be significantly superior to Covishield. While Covishield is being administered at ₹780 per dose in private hospitals, Covaxin is being given at ₹1,410 per dose. The private market price announcement for Corbevax came on the day the government opened up vaccination for children in the 12-14 years age group using only this receptor binding, domain-based protein sub-unit vaccine that is administered via intramuscular injection at a gap of 28 days.
Corbevax can be stored at 2 to 8 degrees Celsius. Datla said that even as the company has submitted the interim results of Corbevax’s Phase III trials on kids in the 5-11 years age category to the Indian drug regulator for review, the company intends to test the vaccine on infants as young as six months. Talking about the private market, BE officials said the company was ready to launch the vaccine immediately for the 12-14 years age group as well as adults but expects less than 10% of total vaccine supplies to go to private hospitals as the government had already made Covid-19 vaccines easily available.
On the exports market for Corbevax, Datla said the company has applied for WHO pre-qualification and expects a site inspection to be conducted shortly. “The booster dose trials are underway and, as of now, we have completed the safety component of the study. As a booster against Covishield and Covaxin, it is safe… now the immunogenicity data will have to be tested, assessed and submitted. It should take another 2-3 weeks,” she added.
Datla said this was to ensure government supplies at the most affordable pricing. “It’s a no-profit-no-loss kind of pricing but it won’t help us recover the investments we have made in the deployment of capital infrastructure,” Datla said, pointing out that the company helped save the exchequer about Rs 1,500 crore.
Bio E plans to test vaccine on infants
Datla had earlier indicated to TOIin an exclusive interview that Corbevax would be priced at a premium to Serum Institute’s Covishield as the head-to-head comparator trials it conducted had shown Corbevax’s effectiveness to be significantly superior to Covishield. While Covishield is being administered at ₹780 per dose in private hospitals, Covaxin is being given at ₹1,410 per dose. The private market price announcement for Corbevax came on the day the government opened up vaccination for children in the 12-14 years age group using only this receptor binding, domain-based protein sub-unit vaccine that is administered via intramuscular injection at a gap of 28 days.
Corbevax can be stored at 2 to 8 degrees Celsius. Datla said that even as the company has submitted the interim results of Corbevax’s Phase III trials on kids in the 5-11 years age category to the Indian drug regulator for review, the company intends to test the vaccine on infants as young as six months. Talking about the private market, BE officials said the company was ready to launch the vaccine immediately for the 12-14 years age group as well as adults but expects less than 10% of total vaccine supplies to go to private hospitals as the government had already made Covid-19 vaccines easily available.
On the exports market for Corbevax, Datla said the company has applied for WHO pre-qualification and expects a site inspection to be conducted shortly. “The booster dose trials are underway and, as of now, we have completed the safety component of the study. As a booster against Covishield and Covaxin, it is safe… now the immunogenicity data will have to be tested, assessed and submitted. It should take another 2-3 weeks,” she added.
Source link
